The ongoing study could significantly impact the stock performance of Regeneron and Sanofi, as successful results may enhance their market position and investor confidence. The development of ...

Nektar Therapeutics is fairly valued based on rNPV modeling, but multiple near-term catalysts could drive upside. Learn why ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Anabelle Terry, a slender, self-possessed 13-year-old, has heard the peanut butter story her entire life. A visit to an ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage study, but that was less than previous trial results for Novo Nordisk's ...

Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential launch of its dermatitis cream in China as well as various clinical ...

Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the year.

Senate Minority Leader Vicente Sotto III said Vice President Sara Duterte’s impeachment trial should not be dismissed forthwith.